AccueilNTLA • NASDAQ
add
Intellia
Dernière clôture
12,02 $
Variation sur la journée
9,93 $ - 11,43 $
Plage sur l'année
9,93 $ - 34,87 $
Capitalisation boursière
1,04 Md USD
Volume moyen
2,36 M
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
NASDAQ
Actualités
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (USD) | sept. 2024info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | 9,11 M | -24,02 % |
Charges d'exploitation | 30,50 M | 3,73 % |
Résultat net | -135,71 M | -11,04 % |
Marge bénéficiaire nette | -1,49 k | -46,15 % |
Bénéfice par action | -1,34 | 2,90 % |
EBITDA | -142,16 M | -10,36 % |
Taux d'imposition effectif | — | — |
Bilan
Total des actifs
Total du passif
| (USD) | sept. 2024info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 658,11 M | -23,01 % |
Total des actifs | 1,17 Md | -5,63 % |
Total du passif | 210,74 M | 2,33 % |
Total des capitaux propres | 962,62 M | — |
Actions en circulation | 101,85 M | — |
Ratio cours/valeur comptable | 1,27 | — |
Rentabilité des actifs | -30,61 % | — |
Retour sur capitaux | -33,80 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (USD) | sept. 2024info | Variation Y/Y |
|---|---|---|
Résultat net | -135,71 M | -11,04 % |
Trésorerie (opérations) | -84,84 M | 16,32 % |
Trésorerie (invest.) | -7,71 M | -109,70 % |
Trésorerie (financement) | 82,19 M | 330,28 % |
Variation nette en trésorerie | -10,35 M | -272,58 % |
Flux de trésorerie dispo. | -35,80 M | 44,08 % |
À propos
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
CEO
Date de fondation
2014
Siège social
Site Web
Employés
526
